For stroke patients, late administration of tenecteplase improved clinical outcomes in situations in which thrombectomy was not available immediately, according to the Chinese TRACE-III trial.

Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding the effectiveness of tenecteplase ...

Ischemic strokes occur when there is blocked blood flow to the brain, something that can result in permanent disability. Doctors can use certain medications to dissolve blood clots when they are the ...

Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. We ...

PHOENIX -- Selected stroke patients did not benefit clinically from having the window of tenecteplase therapy extended beyond the first few hours of stroke onset, the randomized TIMELESS trial found.

BASEL, Switzerland—Multiple randomized trials presented last week at the European Stroke Organisation Conference (ESOC) 2024 have bolstered the case that tenecteplase (TNK) is an effective—if not ...

Treatment with the clot-busting drug tenecteplase given between 4.5 and 24 hours after stroke onset improved functional outcomes compared with standard therapy, according to a new study. The ...

BARCELONA, Spain — A new individual patient-level meta-analysis confirms that the newer bolus thrombolytic, tenecteplase, is noninferior to alteplase for acute ischemic stroke — and may even offer ...

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates. HealthDay ...

BASEL, Switzerland—Tenecteplase doesn’t seem to be a good option for patients with mild, nondisabling ischemic strokes, even when they have a proven intracranial occlusion, according to the results of ...